We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

6 hedge funds and large institutions have $687K invested in XTL Biopharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 5 → 6 (+1)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

26% less capital invested

Capital invested by funds: $927K → $687K (-$240K)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$33.9K
2
Morgan Stanley
Morgan Stanley
New York
+$186

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$371
Name Holding Trade Value Shares
Change 		Change in
Stake
NC
1
Noked Capital
Israel
$286K – – –
NI
2
Noked Israel
Israel
$286K – – –
Morgan Stanley
3
Morgan Stanley
New York
$49K +$186 +25 +0.3%
Invesco
4
Invesco
Georgia
$35K – – –
Citadel Advisors
5
Citadel Advisors
Florida
$26K +$33.9K +4,564 New
UBS Group
6
UBS Group
Switzerland
$5K -$371 -50 -6%

XTLB Hedge Fund Activity: Q3 2019 in Review

6 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2019, worth a combined $687K — down 26% from $927K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.9K. The largest seller was UBS Group, cutting an estimated $371.

  • 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2019, up from 5 in Q2 2019.
  • Funds reported $687K of XTL Biopharmaceuticals stock for Q3 2019, down 26% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q3 2019 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q3 2019 was Citadel Advisors, an estimated $33.9K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2019 was UBS Group, an estimated $371 sold.

Based on aggregated 13F filings for Q3 2019.